Wall Street analyst estimates for Xencor, Inc. (XNCR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
Consensus price target
$43.86 (+46 % vs price $29.99)
between $40.00 and $46.00
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $143M | $67.9M – $178M | $-3.07 | 11 |
| 2027E | $122M | $27.7M – $189M | $-3.35 | 11 |
| 2028E | $120M | $56.1M – $325M | $-3.30 | 10 |
Figures in USD · consensus as of October 26, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 24 |
| Hold | 2 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 28 |
| Avg rating (−2 sell to +2 buy) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.33 | ||
| 2026-08-05 | $-0.29 | $-0.80 | +63.8% |
| 2026-05-06 | $-1.71 | $-0.65 | -163.1% |
| 2026-02-25 | $-0.09 | $-0.64 | +85.9% |
| 2025-11-05 | $-0.08 | $-0.72 | +88.9% |
| 2025-08-06 | $-0.41 | $-0.78 | +47.4% |
| 2025-05-07 | $-0.66 | $-0.63 | -4.8% |
| 2025-02-27 | $-0.62 | $-0.81 | +23.5% |
Valuation Ratios
| Price / Book | 5.38 |
| EV / EBITDA | -18.21 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87.5M | $35.7M | $40.6M | $156.7M | $122.7M | $275.1M | $164.6M | $174.6M | $110.5M | $125.6M |
| Cost of Revenue | $51.9M | $71.8M | $97.5M | $118.6M | $169.8M | $192.5M | $199.6M | 0 | $227.7M | $10.5M |
| Gross Profit | $35.6M | -$36.1M | -$56.9M | $38.1M | -$47.1M | $82.6M | -$35.0M | $174.6M | -$117.2M | $115.1M |
| Research & Development | $51.9M | $71.8M | $97.5M | $118.6M | $169.8M | $192.5M | $199.6M | $253.6M | $227.7M | $239.4M |
| Selling, General & Admin | $13.1M | $17.5M | $22.5M | $24.3M | $29.7M | $38.8M | $47.5M | $53.4M | $58.9M | $63.6M |
| Operating Expenses | $65.0M | $89.3M | $120.0M | $24.3M | $29.7M | $38.8M | $47.5M | $307.0M | $61.2M | $292.6M |
| Operating Income | $22.5M | -$53.6M | -$79.4M | $13.8M | -$76.8M | $43.8M | -$82.5M | -$132.4M | -$178.4M | -$177.5M |
| EBITDA | $45.9M | -$40.7M | -$75.9M | $18.1M | -$71.0M | $90.1M | -$45.7M | -$102.0M | -$186.2M | -$47.0M |
| Interest Expense | $21,000 | $13,000 | $16,000 | 0 | 0 | $13,000 | 0 | 0 | $36.6M | $31.9M |
| Pre-tax Income | $24.6M | -$49.4M | -$70.4M | $27.2M | -$69.3M | $82.6M | -$54.5M | -$119.6M | -$234.9M | -$89.4M |
| Income Tax | $991,000 | -$463,000 | 0 | $312,000 | 0 | 0 | $673,000 | $13.7M | $1.6M | $2.5M |
| Net Income | $23.6M | -$48.9M | -$70.4M | $26.9M | -$69.3M | $82.6M | -$55.2M | -$133.1M | -$232.6M | -$91.9M |
| EPS | $0.57 | $-1.05 | $-1.31 | $0.48 | $-1.11 | $1.42 | $-0.93 | $-2.08 | $-3.58 | $-1.24 |
| EPS (Diluted) | $0.56 | $-1.05 | $-1.31 | $0.46 | $-1.11 | $1.37 | $-0.93 | $-2.08 | $-3.58 | $-1.24 |
| Shares Outstanding (Diluted) | 42.4 M | 46.8 M | 53.9 M | 58.5 M | 57.2 M | 60.5 M | 59.7 M | 60.5 M | 65.0 M | 74.2 M |
Price
| Price | $29.99 (closing price, October 28, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: GMAB · CLDX · NRIX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN
Explore sector: Healthcare · Biotechnology
More sections of XNCR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks